Blood Diagnostics With Nanoscale Precision
Utilizing Artificial Intelligence and Nanotechnology to Enhance Detection
TECHNOLOGY PLATFORM
Arrow DX is developing highly sensitive detection chips that can be incorporated into portable sensors.
The versatility of our technology allows for use in a variety of applications ranging from early disease detection to environmental pollutant detection to quality control in the wine industry.
BLOOD DIAGNOSTICS
The ability to detect small molecules, viruses, bacteria, and proteins in blood is an important tool in the fight against disease. Our proprietary technology allows for an enhanced detection method necessary for the early diagnosis of many diseases such as COVID-19, E.coli, and non-alcoholic fatty liver disease (NAFLD) such that an effective treatment can be found thus making it easier for both the patient and physician.
PROTEIN APPLICATIONS
Protein conformational changes are often a strong indicator of a medicine’s effectiveness on an individual patient. Arrow DX is currently developing methods to apply its technology to further the development of biopharmaceuticals and the pursuit of enhanced personalized medicine.
MACHINE LEARNING
Our mission is to harness the powerful applications of machine learning and predictive analytics to enhance diagnostic medicine. Using proprietary algorithms we are working to develop single protein and metabolite sensitivity.
TECHNOLOGY PLATFORM
Arrow DX is developing highly sensitive detection chips that can be incorporated into portable sensors. The versatility of our technology allows for use in a variety of applications ranging from early disease detection to environmental pollutant detection to quality control in the wine industry.
BLOOD DIAGNOSTICS
The ability to detect small molecules, viruses, bacteria, and proteins in blood is an important tool in the fight against disease. Our proprietary technology allows for an enhanced detection method necessary for the early diagnosis of many diseases such as COVID-19, E.coli, and non-alcoholic fatty liver disease (NAFLD) such that an effective treatment can be found thus making it easier for both the patient and physician.
PROTEIN APPLICATIONS
Protein conformational changes are often a strong indicator of a medicine’s effectiveness on an individual patient. Arrow DX is currently developing methods to apply its technology to further the development of biopharmaceuticals and the pursuit of enhanced personalized medicine.
MACHINE LEARNING
Our mission is to harness the powerful applications of machine learning and predictive analytics to enhance diagnostic medicine. Using proprietary algorithms we are working to develop single protein and metabolite sensitivity.
Current News
April 2020
Arrow DX initiates efforts to develop quick, inexpensive, sensitive diagnostics for viruses such as COVID-19, H1N1 as well as bacteria such as E.coli.
June 2021
Arrow Dx presents at the Boston Scientific Connected Patient Challenge VI as a Semi-Finalist.
August 2021
Arrow Dx chosen to present at the 2021 New England Healthcare Executive Network Summer Social.
August 2021
David E. Cohen MD-PhD., renowned expert in liver diseases and Chief of Division of Gastroenterology & Endoscopy at Brigham and Women’s Hospital, Harvard Medical School joins the Arrow Dx scientific advisory board.
Current News
June 2020
Arrow DX has been selected as one of the 15 companies that will compete in the 2020 $200K M2D2 Challenge in Lowell, MA in Fall 2020. The 2020 $200K M2D2 Challenge received 250+ applications this year.
April 2020
Arrow DX initiates efforts to develop quick, inexpensive, sensitive diagnostics for viruses such as COVID-19, H1N1 as well as bacteria such as E.coli.
August 2021
Arrow Dx chosen to present at the 2021 New England Healthcare Executive Network Summer Social.
August 2021
David E. Cohen MD-PhD., renowned expert in liver diseases and Chief of Division of Gastroenterology & Endoscopy at Brigham and Women’s Hospital, Harvard Medical School joins the Arrow Dx scientific advisory board.
About Us
Arrow DX is building highly sensitive chips which will detect chemical and biological molecules with enhanced sensitivity in solution. The versatility of the technology allows its use in a variety of environments.
One of the most important areas that the company is focusing on is the detection of biological and chemical molecules in blood, water, and saliva.
The most important aspects of the technology are its portability, ease of use, and versatility at detecting a wide range of compounds.
Key Collaborators
Nicholas Brown, Ph.D., Assistant Teaching Professor in Data Science, Northeastern University
Brian Cunningham, Ph.D., Donald Biggar Willet Prof of Engineering, Univ. of Illinois, Urbana-Champaign
Scientific Advisory Board
Sanjiv Chopra, M.B.B.S., M.A.C.P., Harvard Medical School & James Tullis Firm Chief, Department of Medicine, at Beth Israel Deaconess Medical Center
David E. Cohen MD-PhD., Chief of Division of Gastroenterology & Endoscopy at Brigham and Women’s Hospital, Harvard Medical School
David P. Nunes, MD, Director of Hepatology, Assoc. Professor of Medicine, Boston Univ. School of Medicine
Joe DiStefano III, Ph.D., Distinguished Professor of Computer Science and Medicine, University of California, Los Angeles
Board of Advisors
Robert Buzzelli, Senior Managing Director at TeraNova Capital Partners and Shareholder of New World Financial Holdings
Brian Christie, Executive Producer at the Boomer Show, Former CNN anchor
